Trial Profile
A Phase III, Double Blind, Mulit-Centre, Randomised Placebo Controlled, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirez With Continuing Central Nervous System (CNS) Toxicity to TMC125.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Etravirine (Primary) ; Efavirenz; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Adverse reactions
- 20 Nov 2009 Actual patient number (24) added as reported by ClinicalTrials.gov.
- 20 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Nov 2008 New trial record.